MedTrace Logo

To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese

NCT06396429 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 567

Last updated 2025-07-11

No results posted yet for this study

Summary

The study aims to evaluate the efficacy and safety of HRS9531 in subjects with overweight or obese for 48 weeks.

Conditions

  • Overweight or Obesity

Interventions

DRUG

HRS9531 injection

HRS9531 injection; low dose

DRUG

HRS9531 injection

HRS9531 injection; medium dose

DRUG

HRS9531 injection

HRS9531 injection, high dose

DRUG

Placebo

blank preparation, participants received matching placebo.

Sponsors & Collaborators

  • Fujian Shengdi Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-13
Primary Completion
2025-07-07
Completion
2025-07-07

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06396429 on ClinicalTrials.gov